Suzhou Ribo Life Science Co., Ltd. announced the company has received the approval from the CDE of the NMPA for the clinical trial application of its innovative PCKS9 targeting oligonucleotide drug product RBD7022 to conduct the First-In-Human clinical trial in China.

Suzhou Ribo Life Science Co., Ltd. has announced the successful completion of two phase II clinical trials of ISIS 449884, an antisense oligonucleotide（ASO）drug for treatment of Type 2 Diabetes Mellitus (T2DM).

Ribo Life Science Co., Ltd. (Ribo) recently announced the completion of "A randomized, double-blind, placebo-controlled, single-dose escalating Phase I clinical study to evaluate the safety and pharmacokinetics of RBD1016 in healthy subjects" of its Class 1 siRNA drug for chronic hepatitis B in Australia.

Suzhou Ribo Life Science Co., Ltd. has recently obtained an implied license for clinical trials of its innovative ASO drug ISIS 560131, which had been introduced and developed by Ribo, following review by the Center for Drug Evaluation under the National Medical Products Administration.

Suzhou Ribo Life Science Co., Ltd. today announced that its phase II clinical trial of ISIS449884 Injection, an ASO for the treatment of type 2 diabetes, had completed the enrollment of the first patient and the subject was successfully administered the first dose of study drug.

Recently, the Center for Drug Evaluation, National Medical Products Administration completed the technical review on the application for a clinical trial of a new oligonucleotide therapeutics for the treatment of type 2 diabetes submitted by Suzhou Ribo Life Science Co., Ltd., and issued the Notice for Clinical Trial.